Immix Biopharma, Inc. (Nasdaq: IMMX) has completed an underwritten registered offering of 11,363,637 common shares priced at $11.00 each, generating approximately $117.1 million in net proceeds after underwriting discounts, commissions and other offering expenses. The company plans to use the funds for NXC-201 development, working capital and general corporate purposes. J.P. Morgan served as sole book-running manager, with participation from leading U.S. biotechnology institutional investors and mutual funds. NXC-201 is a BCMA-targeted CAR-T (engineered immune-cell therapy) candidate being studied in relapsed/refractory AL Amyloidosis, a disease in which toxic light chains can damage the heart, kidneys and liver. The candidate is under evaluation in the U.S. multi-center NEXICART-2 study, which has a potentially registrational design, and has received Breakthrough Therapy Designation and Regenerative Medicine Advanced Therapy designation from the US FDA, plus Orphan Drug Designation from the FDA and the EMA.